• Clarity Medical issued supplemental findings from an updated FTI Consulting investigation report dated Sept. 7, 2026.
• FTI kept its conclusion that alleged payments tied to WIT and Proyan were substantiated, including HKD 5.68 million paid to WIT.
• Most other corporate governance allegations remained not substantiated, including claims involving Innovative Vision, UOA contracts, and director conduct.
• FTI said alleged IPO-related private share arrangements involving Dr. Tse looked credible, but key terms and effects remained unresolved.
• Trading has been suspended since April 15, 2025, with the suspension to remain in place until further notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Medical Group Holding Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12330345), on September 11, 2026, and is solely responsible for the information contained therein.